("MicroSalt" or the "Company")
Trading Update
MicroSalt (AIM:SALT), a leading manufacturer of full-flavour natural salt with approximately 50% less sodium, is pleased to provide the following trading update and continuing advancement of its B2B bulk business.
Unaudited sales for the 10 months ended
In its H1 2025 Trading Update on
Importantly, the depth and breadth of MicroSalt's relationships with Customer 3 continue to expand, with the signing of a non-binding term sheet outlining a proposed four-year Joint Development Agreement ("JDA") between Customer 3 and MicroSalt to facilitate the global joint development of new solutions for reduction of sodium content in food products while delivering familiar salty taste.
On
Accordingly, the Company is now projecting 2026 sales to total
"Our success in 2025 stems from focused strategic efforts to build a long lived, sustainable organisation that not only delivers healthier foods, but that also delivers top line revenue and investor returns. The projections for 2026, 2027 are based upon our existing volume commitments and as we scale, we expect enhanced efficiencies and additional product development to support continued success. 2025 serves as a foundational building block by providing impeccable reference sales that will solidify our position in the market going forward."
Enquiries:
|
|
|
|
|
|
|
|
|
|
Zeus (Nominated Adviser and Broker) |
+44 (0)20 3829 5000 |
|
|
|
|
|
|
|
|
+44 (0)20 4582 3500 |
|
|
|
About MicroSalt
MicroSalt® is disrupting the global salt market with its patented, full-flavour, low-sodium salt designed for both food manufacturers and consumers. Using proprietary micron-sized particles, MicroSalt® delivers the same salty taste as traditional salt with approximately 50% less sodium, offering a scalable solution to one of the world's most pressing health challenges. Year to date through 2025, MicroSalt® has contributed to more than 634M servings made healthier.
Excess sodium consumption is a leading contributor to cardiovascular disease, the world's number one cause of death.
Operational since 2018, MicroSalt® has established a defensible IP portfolio, holding a granted US patent and 14 pending applications worldwide. These protections create significant barriers to entry in a market expected to grow exponentially as regulation and consumer demand accelerate.
MicroSalt® is ideally positioned for scale and market leadership, with clear pathways into food manufacturing, consumer channels, and ultimately the broader £10+ billion global salt market. MicroSalt® is more than a healthier alternative-it is a disruptive, category-defining solution poised to deliver significant commercial and societal impact.
For more information, please visit www.microsaltinc.co or follow on X @microSaltPLC.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the